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White adipose tissue (WAT) is considered an endocrine organ. When present in excess, WAT can influence 
metabolism via biologically active molecules. Following unregulated production of such molecules, 
adipose tissue dysfunction results, contributing to complications associated with obesity. Previous studies 
have implicated pro- and anti-inflammatory substances in the regulation of inflammatory response and 
in the development of insulin resistance. In obese individuals, pro-inflammatory molecules produced by 
adipose tissue contribute to the development of insulin resistance and increased risk of cardiovascular 
disease. On the other hand, the molecules with anti-inflammatory action, that have been associated with 
the improvement of insulin sensitivity, have your decreased production. Imbalance of these substances 
contributes significantly to metabolic disorders found in obese individuals. The current review aims to 
provide updated information regarding the activity of biomolecules produced by WAT.
Uniterms: Obesity. Inflammation. Adipose tissue. Adipokines. Insulin resistance.
O tecido adiposo branco (WAT) é considerado um órgão endócrino, que, em excesso, é capaz de 
controlar o metabolismo, pela ação de moléculas biologicamente ativas. A produção desregulada destas 
substâncias pela disfunção do tecido adiposo pode contribuir para as complicações presentes na obesidade. 
As pesquisas atuais têm esclarecido fatores e mecanismos envolvidos na atuação de substâncias pró e 
anti-inflamatórias na modulação da inflamação e da resistência à insulina. Em indivíduos obesos, as 
moléculas pró-inflamatórias produzidas pelo tecido adiposo têm sido implicadas como fator contribuinte 
para o desenvolvimento da resistência à insulina e aumento do risco de doença cardiovascular. Por outro 
lado, as moléculas com ação anti-inflamatória, que atuam na melhora da sensibilidade à insulina, têm 
sua produção reduzida. O desequilíbrio entre essas substâncias contribui de forma significativa para as 
desordens metabólicas presente em indivíduos obesos. Assim, esta revisão visa a trazer informações 
atualizadas sobre a atuação de moléculas secretadas pelo tecido adiposo.
Unitermos: Obesidade. Inflamação. Tecido adiposo. Adipocinas. Resistência à insulina.
INTRODUCTION
Obesity is a major worldwide health problem and is 
strongly associated with a number of diseases, including 
type 2 diabetes mellitus (T2DM), insulin resistance, 
atherosclerosis, and ischemic heart disease, which reduce 
life expectancy. Collectively, these conditions have serious 
personal, economic, and social consequences. Increasing 
evidence indicates that obesity is causally linked to a 
chronic low-grade inflammatory state, shown by increased 
levels of inflammatory markers (Hotamisligil, Erbay, 
2008; Goldfine et al., 2010; Torres-Leal et al., 2010). 
This contributes directly to the development of obesity-
related diseases, particularly metabolic diseases (Ouchi 
et al., 2011).
White adipose tissue (WAT) is considered an 
endocrine organ. When present in excess, it secretes 
biologically active molecules that influence metabolism 
by means of adipocyte dysfunction (Fonseca-Alaniz et 
al., 2006; Fonseca-Alaniz et al., 2007). In this regard, 
L. M. Martins, A. R. S. Oliveira, K. J. C. Cruz, F. L. Torres-Leal, D. N. Marreiro678
several studies have been designed to better understand the 
regulatory functions of WAT. In recent years, several factors 
secreted by WAT have been identified that stimulate pro-
inflammatory responses and metabolic dysfunction, thereby 
promoting the development of obesity and associated 
metabolic disorders. These findings support the theory that 
unbalanced production of anti- and pro-inflammatory agents 
secreted by abdominal visceral adipose tissue contributes 
significantly to the development of metabolic diseases in the 
modern world (Ouchi et al., 2011; Capurso, Capurso, 2012).
MOLECULES RELEASED BY ADIPOSE TISSUE
In recent decades, the physiological action of pro-and 
anti-inflammatory molecules has been investigated as well 
as the main factors and mechanisms that influence metabolic 
disorders in obesity, as shown in Table I and Figure 1.
Adipokine synthesis is regulated by adiposity, and 
those with pro-inflammatory action are directly related 
to metabolic dysfunctions found in obesity. Moreover, 
the levels of anti-inflammatory factors in plasma and 
in the adipose tissue are decreased in obese individuals 
compared with lean individuals (McGown, Birerdinc, 
Younossi, 2014; Ouchi et al., 2011).
SFRP5
SFRPs (Secreted frizzled-related proteins) are a group 
of glycoproteins secreted by adipocytes which are capable 
of binding to both, Wnt and Frizzled receptors (Rattner et 
al., 1997). Studies in mice have demonstrated that SFRP5 is 
predominantly expressed in adipocytes; however, in humans 
TABLE I - Pro-and anti-inflammatory adipokines and their functions
Pro-inflammatory adipokines Function
Leptin Controls appetite through the central nervous system, increases TNF-α and IL-6 production 
in obesity
Adipsin Activates the alternative complement pathway
Resistin Increases insulin resistance
RBP-4 Involved in systemic insulin resistance
Lipocalin 2 Promotes insulin resistance and inflammation
TNF-α Reduces insulin sensitivity, induces lipolysis
IL-6 Reduces insulin sensitivity, induces lipolysis
IL-18 Induces expression of adhesion molecules in endothelial cells and macrophage infiltration in 
the blood vessels
Anti-inflammatory adipokines Function
Adiponectin Increases insulin sensitivity and anti-apoptotic and pro-angiogenic effects
SFRP5 Improves insulin sensitivity, suppresses pro-inflammatory Wnt signaling
Adapted from Ouchi et al., 2010. RBP4, retinol binding protein-4; TNF-α, tumor necrosis factor-α; IL, interleukin; SFRP5, secreted 
frizzled-related protein 5
the expression of this protein occurs in the cytoplasm of 
mature adipocytes (Koza et al., 2006; Schulte et al., 2012). 
Researchers investigating mRNA expression of SFRP5 and 
other adipokines during adipogenesis observed a significant 
increase in the expression of SFRP5 during adipogenesis 
(Lv et al., 2012).
SFRP5 is an important anti-inflammatory adipokine 
that can prevent obesity and consequently improve insulin 
sensitivity (Hu, Deng, Qu, 2013; Lv et al., 2012). Studies 
have shown that adipose tissue from lean individuals 
secretes larger amounts of SFRP5. Moreover, this protein 
acts by reducing the production of pro-inflammatory 
adipokines, such as tumor necrosis factor-α (TNF-α), 
interleukin-6 (IL-6), and monocyte chemotactic protein-1 
(MCP-1). However, TNF-α can reduce SFRP5 expression 
by inhibiting adipocyte differentiation and thus, promoting 
pro-inflammatory signaling via Wnt (Oh, Olefsky, 2010).
Another effect attributed to the adipokine is the 
ability to bind to Wnt-5a, preventing the activation of 
pro-inflammatory proteins, thereby contributing to signal 
transduction in the insulin signaling pathway (Ouchi 
et al., 2010). Yet, obesity leads to decreased SFRP5 
expression and increased Wnt-5a expression in adipocytes, 
activating the c-jun amino (N)-terminal kinase 1 (JNK-1) 
pathway and triggering a pro-inflammatory response. 
The activation of JNK-1 impairs the activity of a target 
protein called insulin receptor substrate-1 (IRS-1) leading 
to suppressed insulin signaling and development of insulin 
resistance (Oh, Olefsky, 2010; Ouchi et al., 2010).
In obese rats, Ouchi et al. (2010) observed reduced 
SFRP5 expression and increased Wnt-5a expression. 
This confirms that detectable serum levels of Wnt-5a 
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and SFRP5 are present in obese individuals and these 
bioactive peptides can be affected by level of nutrition. 
Moreover, SFRP5 exhibited a rapid response to caloric 
restriction and, after four weeks of dietary intervention, the 
concentration increased significantly (Schulte et al., 2012).
ADIPONECTIN
Adiponectin is produced and secreted exclusively by 
adipocytes and is found in human plasma at concentrations 
ranging from 3 to 30 μg/mL. This adipokine consists of a 
carboxy-terminal globular domain that binds to two cell 
surface receptors, adiponectin receptor-1 (AdipoR1) and 
adiponectin receptor-2 (AdipoR2), expressed differently in 
various tissues, including WAT. AdipoR1 is predominantly 
expressed in skeletal muscle, whereas AdipoR2 expression 
is high in the liver (Folco et al., 2009; Kadowaki, 
Yamauchi, Kubota, 2008). 
Several biochemical processes are thought to be 
regulated by adiponectin, including activation of AMP-
activated protein kinase (AMPK) and the peroxisome 
proliferator activated receptor-α (PPAR-α). AMPK 
activation is dependent on signaling via AdipoR1 while 
AdipoR2 appears to be essential for regulating PPAR-α 
gene expression (Ouchi et al., 2003; Yamauchi et al., 2002; 
Dyck, 2009; Aprahamian, Sam, 2011; Lin, Li, 2012).
Adiponectin plays an important role in lipid and 
glucose homeostasis, both directly and as a modulator 
of insulin sensitivity (Vu, Riddell, Sweeney, 2007). In 
addition, it has anti-inflammatory, antiapoptotic, and 
proangiogenic activity, but mechanisms for these are not 
well known (Krentz, Von Mühlen, Barrett-Connor, 2009; 
Landskroner-Eiger et al., 2009).
The mechanism by which adiponectin reduces the 
activation of inflammatory cells includes inhibition of 
lipopolysaccharides, decreased T-lymphocyte-activated 
CXC chemokine receptor 3 (CXCR3) ligand expression 
on macrophages, decreased phosphorylation of Inhibitor 
of kappa B (IkB), JNK, signal transducer and activator 
of transcription 3 (STAT3), and p38, as well as increased 
expression of IL-10 in leukocytes and genes encoding anti-
inflammatory proteins such as A20, BCl3, tumor necrosis 
factor (TNF) receptor-associated factor 1 (TRAF1), 
suppressor of cytokine signaling protein 3 (SOCS3), 
and A20-binding inhibitor of NF-kappa-B activation-3 
(ABIN3) (Folco et al., 2009). 
FIGURE 1 - Mechanisms involved in insulin resistance and inflammation present in obesity RBP4, retinol binding protein-4; TNF-α, 
tumor necrosis factor-α; IL, interleukin; MCP-1, monocyte chemotactic protein-1; SFRP5, secreted frizzled-related protein 5; LPS, 
lipopolysaccharide; TLR-4, toll-like receptor 4; JNK, c-jun amino (N)-terminal kinase; STAT3, signal transducer and activator of 
transcription 3; NF-κB, nuclear factor kappa B; IKK, I kappa B kinase; IRS-1, insulin receptor substrate-1; IR, insulin receptor; 
TRAF1, tumor necrosis factor receptor-associated factor 1; GLUT4, translocation of glucose transporter 4; SOCS-3, suppressor 
of cytokine signaling protein-3; TRAF, tumor necrosis factor receptor-associated factor; IRAK, interleukin 1 receptor-associated 
kinase; PI3K, phosphoinositide 3-kinase; JAK, janus kinase; TAK, transforming growth factor (TGF)-activated kinase β; CD14, 
cluster of differentiation-14; MD2, Myeloid differentiation protein-2.
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Another action of adiponectin is related to 
macrophage polarization, where M1 type is pro-
inflammatory and M2 is anti-inflammatory. Adiponectin 
mRNA reduces M1-type markers, such as TNF-α and MCP-
1, and stimulates gene expression of M2 macrophages. 
Taken together, this confirms that adiponectin has 
regulatory effects on macrophage polarization, indicating 
that high expression of this adipokine favors the anti-
inflammatory phenotype (Ohashi et al. 2010).
Circulating adiponectin levels are reduced in 
humans as well as in rodent models of obesity and 
T2DM (Krentz, Von Mühlen, Barrett-Connor, 2009). 
Moreover, accumulation of visceral fat is associated with 
hypoadiponectinemia (Nakamura et al., 2009), indicating 
that the synthesis of adiponectin is impaired in obese 
individuals. Accordingly, adiponectin production by 
adipocytes is inhibited by pro-inflammatory factors, such 
as TNF-α, IL-6, and IL-1β, as well as by hypoxia and 
oxidative stress (Ouchi et al., 2003; Berg, Scherer, 2005; 
Deng, Scherer, 2011).
In contrast, PPARγ agonists such as thiazolidinediones 
promote higher expression and secretion of adiponectin 
via PPARγ activation. Therefore, adiponectin is considered 
a promising candidate in the development of drugs to treat 
obesity, insulin resistance, T2DM, and other metabolic 
diseases (Wang, Scherer, 2008; Liu, Liu, 2010; Ouchi et 
al., 2011).
Several clinical observations support the association 
between adiponectin levels and obesity associated with 
metabolic dysfunction. First, plasma adiponectin levels 
correlate negatively with visceral fat accumulation. 
Second, plasma adiponectin levels are reduced in T2DM 
patients. Third, high adiponectin concentrations are 
associated with reduced risk of developing T2DM (Ouchi 
et al., 2011). Hypoadiponectinemia has been found in 
several cardiovascular and metabolic diseases in humans, 
including T2DM, lipodystrophy, non-alcoholic fatty liver 
disease, hypertension, and coronary artery disease (Deng, 
Scherer, 2011).
Many of the beneficial effects of adiponectin occur 
via AMPK upregulation in the liver and skeletal muscle 
(Yamauchi et al., 2002). Adiponectin phosphorylates 
AMPK, thus inhibiting acetyl CoA carboxylase (ACC) and 
reducing malonyl CoA levels. Malonyl CoA is an inhibitor 
of carnitine palmitoyl transferase-1, an enzyme limiting 
fatty acid oxidation. Consequently, reduction in the levels 
of malonyl-CoA, which is promoted by AMPK, increases 
fatty acid oxidation. AMPK also stimulates PPAR-α 
which increases the expression of enzymes involved 
in β-oxidation of fatty acids, resulting in improved 
insulin sensitivity. Additionally, the peripheral tissues 
show reduced levels of free fatty acids, which prevents 
lipotoxicity and impaired insulin receptor signaling by 
fatty acids (Viollet et al., 2006; Puglisi, Fernandez, 2008).
Adiponectin also reduces hepatic  glucose 
production by directly inhibiting gluconeogenic enzymes 
(phosphoenolpyruvate carboxykinase and glucose-6-
phosphate) and by improving glycemic control via insulin 
sensitivity (Yamauchi et al., 2002; Puglisi, Fernandez, 
2008). Increased AMPK, as a result of adiponectin action, 
promotes higher fatty acid oxidation in skeletal muscle and 
decreases the distribution of nonesterified fatty acids to 
the liver, leading to reduced triacylglycerol synthesis and 
very low density lipoprotein cholesterol (VLDL) secretion 
(Puglisi, Fernandez, 2008).
LEPTIN
Leptin, a 16-kDa protein containing 167 amino acids, 
is highly hydrophilic and is synthesized by WAT. It acts on 
food control and energy expenditure via Lepr-b receptor on 
neurons. These neurons, such as Lepr-b, are required for 
leptin action (Myers et al., 2009). In general, hypothalamus, 
midbrain, and brainstem, where these neurons are located, 
are known to play important roles in the energy metabolism 
and balance (Sadagurski et al., 2012).
The regulation of energy metabolism by leptin is 
two-fold. The first action is to stimulate the expression of 
neuropeptides that promote inhibition of food intake and 
increase total energy expenditure within parvocellular 
neurons in the hypothalamic arcuate nucleus (ARC). This 
involves a population of neurons from the paraventricular 
nucleus promoting increased sympathetic tone. The 
second action is to inhibit the expression of neuropeptide Y 
(NPY) and agouti peptide (AGRP), involved in increased 
food intake and reduced energy expenditure, acting on 
a similar population of neurons within the ARC itself 
(Fonseca-Alaniz et al., 2007).
Under normal conditions, leptin activity increases 
the expression of anorexigenic peptides and decreases 
the expression of orexigenic peptides in specific neuron 
populations. This decreases appetite and increases energy 
expenditure, contributing to the maintenance of metabolic 
balance. In contrast, the effects of leptin on energy 
homeostasis is decreased in pathological conditions such 
as obesity, due to physiological activity from the excessive 
adipose tissue (St-Pierre, Tremblay, 2012).
It is well established that obese individuals are less 
sensitive to leptin action, and that they are resistant to this 
hormone. Several mechanisms have been proposed to 
explain this resistance, including impaired leptin transport 
across the blood-brain barrier, endoplasmic reticulum stress 
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and inflammation, as well as attenuated leptin signaling by 
SOCS3 and protein tyrosine phosphatase (PTP) (Ozcan et 
al., 2009; Zhang, Scarpace, 2009; Myers et al., 2012).
Recent studies indicate that the changes caused by 
obesity are mediated, at least in part through activation 
of Toll-like receptors (TLRs) in various tissues and that 
this signaling contributes to the development of obesity 
associated with insulin resistance (Könner, Brüning, 2011; 
Fortis et al., 2012). Obese individuals and those with 
T2DM have elevated gene and protein TLR4 expression 
in muscle tissue, which correlates with the severity of 
insulin resistance in these conditions. Abnormal TLR4 
expression and signaling caused by elevated levels of 
free fatty acid (FFA) may contribute to the pathogenesis 
of insulin resistance in humans. Diets high in saturated 
fats are considered causes of leptin and insulin resistance 
induced by diet. Saturated fat acts as a TLR4 ligand, thus 
activating cascade of JNK and IKK signaling pathways, 
and inhibiting insulin action in the skeletal muscle, liver 
and WAT (Wellen, Hotamisligil, 2005; Reyna et al., 2008).
Leptin is involved in insulin sensitivity through the 
immune response and other mechanisms, such as signaling 
in neuron receptors. In this regard, studies have revealed 
that IRS-2 signaling in Lepr-b neurons is the key mediator 
for insulin/insulin-like growth factor (IGF) signaling in the 
brain and in controlling energy balance. Action of insulin, 
IGF1 and IGF2 via the receptor tyrosine kinase sends 
signals to proteins such as the insulin receptor substrate, 
IRS-1, IRS-2, and IRS-4 (White, 2010; Sadagurski et al., 
2012).
Recently, researchers have highlighted antidiabetic 
action of leptin in experimental models (Fujikawa et 
al., 2013). Leptin is secreted primarily from WAT and 
binds to its receptor (LEPR) in GABAergic neurons, that 
secrete gamma-aminobutyric acid (GABA) as well as 
pro-opiomelanocortin neurons (POMC), thus exerting 
antidiabetic action in insulin deficient conditions. Leptin 
inhibits AGRP/NPY/GABA neurons, while it activates 
POMC neurons in the ARC. The anti-diabetic activity of 
leptin probably occurs in second-order neurons located 
in the paraventricular nucleus (PVH), the lateral (LH), 
and ventromedial (VMH) hypothalamus, or brainstem. 
The LEPR in GABAergic neurons in other hypothalamic 
regions, such as the dorsomedial hypothalamus (DMH) 
or LH may also mediate leptin activity on glucose 
homeostasis. Leptin suppresses hyperglucagonemia and 
increases glucose utilization in peripheral tissues such 
as brown adipose tissue and skeletal muscle, through its 
activity on GABAergic and POMC neurons (Fujikawa et 
al., 2013; Kahn, Minokoshi, 2013).
The adipokine leptin is structurally similar to the 
family of cytokines with helicoidal form, such as IL-2 and 
growth hormone, promoting a pro-inflammatory activity. 
Here, leptin increases the production of TNF-α and IL-
6, thus stimulating the production of reactive oxygen 
species (ROSs). Leptin also promotes cell differentiation 
and migration responses by monocytes, in addition to 
stimulating the production of CC-chemokine ligands 
(CCL-3, CCL-4, CCL-5) by activating JAK2-STAT3 
in macrophages (Santos-Alvarez, Goberna, Sánchez-
Margalet, 1999; Kiguchi et al., 2009).
In rodents and humans, leptin deficiency results in 
obesity due to hyperphagia and low energy expenditure 
by the central nervous system (CNS), namely low energy 
levels in the presence of sufficient energy reserves. In 
diet-induced obesity, leptin levels are high, reflecting 
increased fat depots (Myers et al., 2010; Torres-Leal et 
al., 2011). Studies in healthy humans have demonstrated 
that moderate weight gain increases the expression of 
adipokines and alters the expression of caveolin 1 in 
WAT. This in turn, affects leptin signaling and inhibits the 
accumulation of lipids in adipose cells (Singh et al., 2012).
RETINOL BINDING PROTEIN 4
Retinol binding protein-4 (RBP-4), a member of 
the lipocalin family, is a vitamin A transporting protein 
in plasma. It is mainly synthesized by hepatocytes and 
secreted into circulation in the form of retinol-RBP 
complex, which provides retinol to the tissues. WAT is the 
second largest site of RBP-4 expression. Recent studies 
have shown that this protein is involved in the induction 
of insulin resistance, and thus, it is considered important 
for the development of T2DM (Blaner et al., 1986; Zhang, 
Yang, Shi, 2005; Bajzová et al., 2008).
RBP-4 levels have a positive correlation with 
adipocyte size and inflammatory markers such as waist 
circumference and body mass index. RBP-4 levels 
are preferably expressed in visceral WAT rather than 
subcutaneous WAT (Klöting et al., 2007; Lee, Lee, Im, 2007; 
Hermsdorff et al., 2011). The expansion of adipocyte tissue 
reduces adiponectin expression and increases circulating 
levels of RBP-4. These changes are associated with low 
oxidation rate of fatty acids, increased gluconeogenesis 
in the liver, decrease in IRS-1 phosphorylation, and 
translocation of glucose transporter (GLUT4), which results 
in insulin resistance (Gavi et al., 2007; Esteve, Ricart, 
Fernández-Real, 2009; Yang et al., 2005).
In childhood obesity, high RBP-4 levels are 
associated with excessive body fat, insulin resistance, 
T2DM, and circulating inflammatory factors, such as 
C-reactive protein (CRP) and IL-6 (Balagopal et al., 
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2007). Furthermore, it was found that IL-8 increases RBP-
4 gene expression in the adipocyte and this can contribute 
to increased incidence of DM (Bobbert et al., 2009).
On the other hand, some studies diverge on the role 
of RBP-4 in obese individuals without insulin resistance. 
Accordingly, Choi et al. (2009) compared RBP-4 levels 
associated with weight loss in non-diabetic obese 
individuals and observed no significant difference between 
the study groups. In contrast, RBP-4 expression, insulin 
resistance, PCR, IL-18, and TNF-α levels decreased 
significantly, while adiponectin increased significantly 
with weight loss in obese women (Broch et al., 2010).
LIPOCALIN 2
Lipocalin 2 (Lcn2), also known as 24p3 or neutrophil 
gelatinase-associated lipocalin, is a 25-kDa glycoprotein 
originally identified in mouse kidney cells and human 
neutrophil granules (Wang et al., 2007; Choi et al., 2008). 
This cytokine is a member of the lipocalin family and has a 
tertiary barrel-shaped structure with a hydrophobic pocket 
that can bind to lipophilic molecules such as retinol, fatty 
acids, and steroids (Esteve, Ricart, Fernández-Real, 2009; 
Ouchi et al., 2011; Kamata et al., 2012).
This protein has been implicated in apoptosis, 
cancer, inflammation, iron homeostasis, and innate 
immunity. In addition to neutrophils, Lcn2 is expressed in 
many tissues including the liver, lung, kidney, adipocytes, 
and macrophages. Several inflammatory stimuli, such as 
lipopolysaccharide and IL-1, can promote Lcn2 expression 
and secretion. Pro-inflammatory transcription factor NF-
κB activates Lcn2 expression by binding to the promoter 
region of gene Lcn2, suggesting its involvement in the 
inflammatory response (Wang et al., 2007; Law et al., 
2010; El-Mesallamy et al., 2012; Kamata et al., 2012).
Lcn2 has been identified as an acute-phase protein 
secreted by WAT and is positively correlated with potential 
effects on obesity, inflammation, apoptosis, and innate 
immunity (Damirchi, Rahmani-Nia, Mehrabani, 2011). 
Lcn2 expression is increased by agents promoting insulin 
resistance, and reduced by thiazolidinediones, indicating 
a role in insulin resistance in obesity (Yan et al., 2007; 
Fried, Greenberg, 2012). Furthermore, high Lcn2 levels 
are associated with a decline in pancreatic β-cell function 
in diabetic patients (El-Mesallamy et al., 2012).
In a study on diabetic and obese (db-db) mice 
conducted by Wang et al. (2007), circulating Lcn2 
levels and its expression were increased in WAT and 
liver compared with those in control mice. In addition, 
serum Lcn2 levels positively correlated with body mass 
index, hypertriglyceridemia, hyperglycemia, and insulin 
resistance, but negatively correlated with high-density 
lipoprotein (HDL-c) in humans. In the same study, 
treatment with rosiglitazone significantly decreased Lcn2 
levels and gene expression. The authors suggest that Lcn2 
is an inflammatory marker closely linked to obesity and 
its metabolic complications.
Lcn2 expression is increased in atherosclerotic 
plaques and myocardial infarction, while it regulates the 
inflammatory response during ischemia and reperfusion 
during heart transplantation. In this regard, Choi et 
al. (2008) identified higher circulating Lcn2 levels in 
individuals with coronary artery disease than those in 
the control group. Additionally they found a positive 
correlation of Lcn2 with body weight, fasting insulin 
levels, and insulin resistance.
Lcn2 has recently been associated with anti-
inflammatory effects. High concentrations of this protein 
in obesity and insulin resistance appear to protect against 
inflammation. Furthermore, Lcn2 regulates PPAR-γ 
in adipocytes as well as its target genes, adiponectin, 
leptin, fatty acid synthase, and lipoprotein lipase. The 
anti-inflammatory function of Lcn2 is associated with 
modulation on PPARγ activity, which, by direct or indirect 
mechanisms, inhibits NF-κB activity. Concomitantly, 
Lcn2 antagonizes the effects of TNF-α in adipocytes 
and macrophages, protecting these cells from TNF-α 
production induced by IL-6 and MCP-1. Thus, Lcn2 
mitigates the effect of TNF-α on glucose uptake and 
reverses the inhibitory effect of TNF-α on leptin and 
adiponectin secretion by adipocytes (Zhang et al., 2008; 
Esteve, Ricart, Fernández-Real, 2009).
INTERLEUKIN-6
Interleukin-6 is a pro-inflammatory cytokine that is 
also involved in insulin resistance found in obesity. IL-6 
levels correlates positively with adiposity in humans, 
wherein, obese individuals have high IL-6 levels and weight 
loss promotes reduced production of this cytokine (Ziccardi 
et al., 2002; Iacobellis, Leonetti, 2005; Ouchi et al., 2011).
IL-6 acts on carbohydrate and lipid metabolism, 
stimulating lipolysis with consequent inhibition of enzyme 
lipoprotein lipase and increased release of free fatty acids 
and glycerol. IL-6 is a central mediator of the acute-phase 
response, and is produced and secreted by endothelial 
cells, smooth muscle cells, monocytes, macrophages, and 
adipocytes, especially visceral adipose tissue (Rexrode 
et al., 2003; Fonseca-Alaniz et al., 2006; Francisco, 
Hernández, Simó, 2006).
IL-6 infusion at doses close to physiological levels in 
healthy humans promotes lipolysis, regardless modulation 
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of catecholamines, glucagon, and insulin. This effect 
occurs through inhibition of lipoprotein lipase (LPL) and 
increased release of FFA and glycerol. IL-6 is secreted 
by macrophages and adipocytes, and its expression can 
be stimulated by high concentrations of catecholamines 
via adrenergic β2- and β3-receptors from WAT (Fonseca-
Alaniz et al., 2007).
IL-6  i s  pos i t ive ly  a s soc ia t ed  wi th  wa i s t 
circumference, suggesting that increased body fat, 
especially central obesity, promotes the development of 
metabolic syndrome and insulin resistance (Rexrode et al., 
2003; Volp et al., 2008; Junqueira, Romêo Filho, Junqueira, 
2009). Some studies show a clear relationship between 
high IL-6 levels and the presence of insulin resistance or 
T2DM. This cytokine reduces insulin-dependent glycogen 
synthesis and glucose uptake in adipocytes through 
increased expression of SOCS-3, a protein that binds to 
and inhibits insulin receptor. Additionally, it negatively 
regulates IRS-1 phosphorylation and transcription (Galic, 
Oakhill, Steinberg, 2010; Torres-Leal et al., 2010).
Studies have shown that higher the body mass index 
and waist circumference, higher the inflammatory markers 
levels. The study conducted by Rexrode et al. (2003) showed 
that women with body mass index greater than 28.3 kg/m² 
have four times the IL-6 levels found in those with body 
mass index within the normal range. Similarly, individuals 
with visceral obesity have significantly higher serum IL-6 
levels than those in eutrophic individuals (Nishida et al., 
2007). By contrast, reduced serum IL-6 levels were found 
in individuals who had weight loss (Esposito et al., 2003).
In a study on overweight male individuals, Spalding 
et al. noted that circulating IL-6 levels were associated 
with visceral obesity whereas TNF-α was associated 
with overall obesity (Spalding et al., 2008). According 
to the author, these results support the hypothesis that 
IL-6 is involved in the hyperinsulinemic state associated 
with excessive visceral fat, whereas TNF-α appears to 
contribute to insulin resistance in overall obesity.
RESISTIN
Resistin (RETN) belongs to the family of cysteine-
rich peptides termed resistin-like molecules (RELM) 
(Steppan et al., 2001). This cytokine is expressed and 
secreted by rodent adipocytes and the name is derived from 
its ability to induce insulin resistance. RETN is associated 
with activation of inflammatory processes (Steppan et 
al., 2001), where circulating levels increase even though 
mRNA levels are reduced, in genetically modified models 
and a high-fat diet (Steppan et al., 2001; Rajala et al., 
2004; Way et al., 2001).
In experimental mouse models, RETN showed 
ability to induce insulin resistance (Steppan et al., 2001) 
and low fasting glucose levels were seen in RETN-
knockout animals due to low hepatic glucose production 
(Banerjee et al., 2004). Ob-ob resistin deficient mice were 
more obese although showing increased insulin sensitivity 
and improved glucose tolerance (Qi et al., 2006).
From this perspective, the ability of RETN to affect 
glucose metabolism is associated with activation of SOCS-
3, an inhibitor of insulin signaling in adipocytes (Steppan 
et al., 2005). Although studies in animal models have 
consistently shown that RETN promotes insulin resistance, 
there is also evidence indicating that this effect in humans 
is less evident (Lee et al., 2003; Heilbronn et al., 2004).
The trimer isoform of RETN is the most bioactive 
and is primarily responsible for hepatic insulin resistance; 
however, it is less abundant (Patel et al., 2004). Although 
RETN was originally identified in WAT, new studies show 
a more systemic pattern of expression, which had led to 
a controversy over the regulation of this adipokine. In 
mice, protein synthesis of RETN is restricted to adipocytes 
(Steppan et al., 2001), whereas, in humans, it is mainly 
produced by macrophages and monocytes, and is not 
detectable in adipocytes (Savage et al., 2001).
Studies in human mononuclear cells show 
that RETN gene transcription is stimulated by pro-
inflammatory cytokines (IL-1, IL-6, and TNF-α) (Kaser 
et al., 2003) and is inhibited by PPARγ agonists in WAT 
(e.g., rosiglitazone), suggesting that the anti-inflammatory 
effect of these agonists is mediated, in part by attenuation 
of RETN transcription (Lehrke et al., 2004).
Moreover, studies performed in mice lacking 
adipocyte-derived mouse RETN, but expressing 
human transgene RETN in macrophages showed that 
pro-inflammatory properties of RETN contribute to 
insulin resistance in vivo (Qatanani et al., 2009). The 
pro-inflammatory role of RETN in mononuclear cells is 
characterized by promoting TNF-α and IL-6 expression 
in these cells (Bokarewa et al., 2005). On the other hand, 
RETN acts by directly antagonizing the anti-inflammatory 
effects of adiponectin in vascular endothelial cells, 
inducing expression of pro-inflammatory molecules, 
such as vascular cell adhesion molecule-1 (VCAM-
1), intercellular adhesion molecule-1 (ICAM-1), and 
pentraxin-3, increasing leukocyte adhesion (Verma et al., 
2003; Kawanami et al., 2004).
TUMOR NECROSIS FACTOR ALPHA
TNF-α, an inflammatory and immunomodulatory 
cytokine that acts directly on the adipocyte, has been 
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implicated in metabolic diseases, including obesity and 
insulin resistance (Puglisi, Fernandez, 2008). This cytokine 
was initially identified as a polypeptide produced by 
macrophages in chronic diseases as well as during infectious 
processes contributing to cachexia (Rose, Komninou, 
Stephenson, 2004). In WAT, TNF-α is synthesized and 
secreted by vascular stromal cells and matrix fractions 
including macrophages, although its mRNA is expressed 
in adipocytes (Fain, Bahouth, Madan, 2004).
Obesity is associated with increased FFA resulting 
from triglyceride lipolysis in the adipocyte. The 
relationship between obesity and inflammation has been 
reported as high TNF-α expression in WAT (De Carvalho, 
Colaço, Fortes, 2006). Studies have shown a positive 
correlation between plasma TNF-α concentrations, body 
mass index, and triacylglycerols. This cytokine is produced 
7.5 times higher by the WAT in obese individuals than that 
in non-obese individuals. Furthermore, there is evidence 
indicating that TNF-α promotes increased production of 
VLDL particles, which may explain its direct relationship 
with plasma triacylglycerols (Deng, Scherer, 2011).
Studies have shown that TNF-α is also associated 
with insulin resistance in obesity. Accordingly, high 
TNF-α expression in subcutaneous WAT promotes 
increased insulin levels in obesity, as typically seen in 
insulin resistance. TNF-α induces insulin resistance by 
promoting lipolysis, consequently promoting increased 
circulating levels of FFA and reduced protein expression 
of GLUT4, insulin receptor, and IRS-1 (Fonseca-Alaniz 
et al., 2007).
In this context, macrophage infiltration in WAT 
results in increased TNF-α secretion, and this, in turn, 
activates both lipolysis and NF-κB, via receptors 
(TNF-R) located in the adipocytes. Furthermore, saturated 
fatty acids (resulting from lipolysis in the adipocytes) 
are involved in TLR activation by macrophages and 
adipocytes. These receptors also favor the activation of 
NF-κB, which increases the secretion of inflammatory 
cytokines in both cells. Thus, IRS-1 phosphorylation is 
reduced, leading to insulin resistance (Fortis et al., 2012).
TNF-α plays a key role in the transcription cascade 
of other cytokines and growth factors in the inflammatory 
process. Elevated TNF-α contributes to the synthesis 
of interleukins such as IL-1, IL-6, and IL-8, which 
in turn induce monocyte adhesion, thus promoting 
the atherosclerotic process (Li, Verma, 2002; Puglisi, 
Fernandez, 2008).
TNF-α activates IkB via kinase complex IKK, 
which in turn leads to polyubiquitination and subsequent 
degradation by IkB protease. Consequently, NF-κB is 
phosphorylated and dissociated from IkB, and translocated 
to the nucleus where it binds to promoter regions of genes 
responsive to NF-κB, thus initiating the transcription of 
pro-inflammatory genes, such as IL-1, IL-6, and TNF-α 
(Li, Verma, 2002; Hayden, Ghosh, 2004). Current studies 
suggest that TNF-α induces IL-6 synthesis by NF-κB 
phosphorylation and that oxidative stress also contributes 
to the synthesis of this cytokine (Tanabe et al., 2010).
WAT from normal individuals is involved in 
adiponectin production by increasing insulin sensitivity. 
However, WAT from obese individuals has impaired 
adiponectin secretion, thus compromising insulin action. 
From this perspective, increased insulin resistance and 
TNF-α expression contribute to decreased adiponectin 
gene expression (Hajri et al., 2011). Increased expression 
of TNF-α and IL-6 confirms that obese diabetic individuals 
have a more severe inflammatory state than that in non-
obese diabetic ones (Goyal et al., 2010).
Human adipocytes exposed to TNF-α exhibit 
reduced PPARβ/δ activity and this effect depends on NF-
κB activation. Moreover, this response is recovered by 
PPARβ/δ agonists, suggesting that inhibition of NF-κB 
by these drugs can avoid metabolic dysfunction in obese 
individuals (Serrano-Marco et al., 2012). Another effect 
attributed to TNF-α is reduced production of zinc α-2 
glycoprotein (ZAG), a protein modulating body weight, 
which hydrolyzes TAG via hormone sensitive lipase 
(HSL), contributing to increased lipid droplets in WAT 
and ectopic accumulation in the liver and other peripheral 
tissues (Rolli et al., 2007; Mracek et al., 2010).
LITAF (LIPOPOLYSACCHARIDE-INDUCED 
TNF-α FACTOR)
LITAF is a transcription factor that binds to a 
regulatory element (CTCCC) in the TNF-α promoter 
region, induces transcription of TNF-α, and is likely to be 
related to the defense against infections. LITAF induced 
by lipopolysaccharide and signal transducer and activator 
of transcription 6 (STAT6B), form a complex in the 
cytoplasm that translocates into the nucleus. Consequently, 
it increases the expression of TNF-α, IL-1α, IL-10, 
interferon-gamma (IFN-γ), and MCP-2 (Tang, Fenton, 
Amar, 2003; Tang et al., 2005; Srinivasan, Leeman, Amar, 
2010).
L I TA F  e x p r e s s i o n  c a n  b e  i n c r e a s e d  b y 
lipopolysaccharide stimulation in human monocytes and 
rat macrophages via activation of receptors TLR2 and 
TLR4 (Tang et al., 2006). Studies have demonstrated 
the relationship between this protein and obesity, insulin 
resistance, and inflammatory cytokines. LITAF is 
activated in obese patients and is involved in inflammation 
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and insulin resistance found in obesity, through regulation 
of TNF-α, IL-6 and MCP-2 expression. Moreover, TLR-4 
is a membrane receptor found in macrophages stimulated 
by both LITAF and FFA, thus initiating the inflammatory 
process via NF-κB (Ji, Dai, Xu, 2011).
LIPOKINE
It is well established that the imbalance between 
energy intake and expenditure has a direct influence on 
adiposity gain (Flowers, Ntambi, 2009). This increase in 
the adipose content can occur in two ways: hypertrophy 
and hyperplasia (Torres-Leal et al., 2010). The ability of 
adipose tissue to expand is considered critical when it 
comes to changes in the energy availability, but this ability 
is limited and is likely to vary among individuals (Gray, 
Vidal-Puig, 2007; Virtue, Vidal-Puig, 2010). Investigators 
suggest that it is not the absolute amount of adipose tissue, 
but the adipocyte ability to expand that affects metabolic 
homeostasis (Gray, Vidal-Puig, 2007; Virtue, Vidal-Puig, 
2010). Furthermore, it is known that adipocyte size is 
critical to changes in both, its role as an endocrine organ, 
and its metabolism (lipogenesis and lipolysis).
Recently, considerable attention has been given to 
the effect of the enzyme stearoyl-coenzyme A desaturase 
(SCD), which primarily affects fat storage (Flowers, 
Ntambi, 2008; Popeijus, Saris, Mensink, 2008; Gong 
et al., 2011). SCD is involved in de novo synthesis of 
monounsaturated fatty acids from saturated fatty acids 
(Smith, Lieberman, Marks, 2005). The main products of 
SCDs are palmitoleic (16:1 ω-7) and oleic (18:1) acid, 
essential for triacylglycerol synthesis (Smith, Lieberman, 
Marks, 2005), from their preferred substrates, palmitic 
(16:0) and stearic acid (18:0), respectively. Two SCD 
isoforms have been observed in humans, SCD1 (mainly 
seen in adipose tissue and liver) and SCD5 (observed in 
the brain and pancreas) (Zhang et al., 1999; Wang et al., 
2005; Zhang, Yang, Shi, 2005).
Studies to date indicate that – amongst the molecules 
synthesized and secreted by WAT – palmitoleic acid, which 
is considered as the most common lipid signaling agent 
with hormonal functions, controls metabolic activities in 
the liver and skeletal muscle, such as stimulating insulin 
action in muscle and suppressing liver steatosis (Cao et 
al., 2008).
Cao et al. point out that palmitoleic acid production 
is higher in fatty acid binding protein-(FABP) or 
chaperone-knockout mice; where these proteins help 
to transport and store the fat absorbed from food into 
adipocytes. This study revealed that impaired lipid storage 
induced by diet causes the adipocytes to synthesize 
their own fat, which in turn increases palmitoleic acid 
production, thereby promoting a healthy metabolism. 
Moreover, these FABP/knockout mice were resistant to 
chronic high fat diet-associated problems, such as heart 
disease, liver steatosis, and diabetes (Cao et al., 2008). 
However, little is known about the effects of lipokine on 
WAT metabolism, as well as in adipogenesis.
Recently, the involvement of palmitoleic acid 
in WAT metabolism (lipogenesis and lipolysis) was 
investigated. The results indicated that palmitoleic acid is 
an important positive modulator of lipolysis in adipocytes 
and acts by increasing protein expression of lipases such as 
ATGL and HSL, through a PPAR-α dependent mechanism 
(Bolsoni-Lopes et al., 2013). However, further studies 
are required to test whether activation of lipolysis by 
lipases and palmitoleic acid has protective effects against 
excessive fat deposition found in obesity.
CONCLUSION
Evidence found in this review suggests that chronic 
inflammatory state associated with obesity, particularly 
visceral fat accumulation, contributes to several metabolic 
and hormonal disturbances. In this regard, it is worth 
noting that excessive adipose tissue increases the 
production of adipokines with pro-inflammatory action at 
the expense of adipokines with anti-inflammatory action. 
Therefore, this article provides information regarding new 
molecules in order to help understand the influence of 
adipokines in adipose tissue-mediated inflammation and 
insulin resistance.
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